GGrantIndex
← Leaderboards

Elizabeth J McFarland

University Of Colorado Denver

Google Scholar ↗PubMed ↗ORCID ↗
$4,371,689
Attributed
$4,371,689
Total exposure
33
Grants
26
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $666K · FY2005–15
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15

Funding mix

By agency

NIH$4,371,689 · 33

By mechanism

U01$2,336,468 · 1
M01$1,701,940 · 31
R01$333,281 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Colorado Denver

Same institution · by research overlap

Others in their field

Top investigators on “Institution”

Research focus

InstitutionFundingComputer Retrieval Of Information On Scientific Projects DatabaseResearch PersonnelGrantUnited States National Institutes Of HealthResourcesSourceHiv InfectionsEnrollmentProtocols, TreatmentChildAdolescentSiteAdultHuman SubjectClinical ResearchPatient Oriented ResearchLabelInfectionDoseAids TherapyQuality Of LifeAnti-Retroviral Agents

Grant awards (46)

University of Colorado Denver Adolescent Trials Network Unit$588,839
U01 · FY2015 · HD · contact PI
University of Colorado Denver Adolescent Trials Network Unit$449,811
U01 · FY2014 · HD · contact PI
University of Colorado Denver Adolescent Trials Network Unit$426,375
U01 · FY2013 · HD · contact PI
University of Colorado Denver Adolescent Trials Network Unit$436,204
U01 · FY2012 · HD · contact PI
University of Colorado Denver Adolescent Trials Network Unit$435,239
U01 · FY2011 · HD · contact PI
PACTG P1025: PERINATAL CORE PROTOCOL$191,811
M01 · FY2007 · RR · contact PI
ACTG #219C: PEDIATRIC LATE OUTCOMES PROTOCOL$184,746
M01 · FY2007 · RR · contact PI
ANTIRETROVIRAL THERAPY PHARMACOKINETICS DURING PUBERTY$76,077
M01 · FY2007 · RR · contact PI
PACTG P1026S: PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUG DURING PREGNANCY$44,899
M01 · FY2007 · RR · contact PI
PACTG P1055: PSYCHIATRIC CO-MORBIDITY IN PERINATALLY HIV CHILDREN AND ADOLESCENT$44,831
M01 · FY2007 · RR · contact PI
PACTG P1047: PHASE II SAFETY AND IMMUNOGENICITY STUDY OF QUADRIVALENT$40,755
M01 · FY2007 · RR · contact PI
PACTG 1020A: BMS232632 IN COMB REGIMENS IN ART-NAIVE & EXPERIENCED HIV CHILDREN$20,378
M01 · FY2007 · RR · contact PI
PACTG P1059$17,660
M01 · FY2007 · RR · contact PI
ATN 024: TRIAL OF THREE HEPATITIS B VACCINATION SCHEMAS IN HIV-POSITIVE YOUTH$17,660
M01 · FY2007 · RR · contact PI
PACTG P1021: EMTRICITABINE IN COMBINATION WITH EFAVIRENZ & DIDANOSINE$10,870
M01 · FY2007 · RR · contact PI
PACTG P1030: LOPINAVIR/RITONAVIR IN HIV-1 INFECTED INFANTS < 6 MONTHS OF AGE$9,508
M01 · FY2007 · RR · contact PI
PACTG 1034: PROTEASE-CONTAINING AND PROTEASE-SPARING HAART REGIMENS$6,795
M01 · FY2007 · RR · contact PI
ACTG #219C: PEDIATRIC LATE OUTCOMES PROTOCOL$191,870
M01 · FY2006 · RR · contact PI
PACTG P1025: PERINATAL CORE PROTOCOL$96,715
M01 · FY2006 · RR · contact PI
PACTG P1021: EMTRICITABINE IN COMBINATION WITH EFAVIRENZ & DIDANOSINE$31,266
M01 · FY2006 · RR · contact PI
PACTG P1026S: PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUG DURING PREGNANCY$17,128
M01 · FY2006 · RR · contact PI
PACTG P1030: LOPINAVIR/RITONAVIR IN HIV-1 INFECTED INFANTS < 6 MONTHS OF AGE$17,055
M01 · FY2006 · RR · contact PI
PACTG 1034: PROTEASE-CONTAINING AND PROTEASE-SPARING HAART REGIMENS$17,055
M01 · FY2006 · RR · contact PI
PACTG 1020A: BMS-232632 IN COMB REGIMENS IN ART-NAIVE & EXPERIENCED HIV CHILDREN$15,490
M01 · FY2006 · RR · contact PI
PACTG P1055, VERSION 10$11,372
M01 · FY2006 · RR · contact PI
PACTG P1045: MORPHOLOGIC & METABOLIC ABNORMALITIES IN VERTICALLY HIV-INFECTED$9,947
M01 · FY2006 · RR · contact PI
ATN 024: TRIAL OF THREE HEPATITIS B VACCINATION SCHEMAS IN HIV-POSITIVE YOUTH$8,528
M01 · FY2006 · RR · contact PI
PACTG P1015: INTENSIFICATION OF HIV-SPECIFIC CD4 & CD8 ACTIVITY BY CYCLING HAART$7,108
M01 · FY2006 · RR · contact PI
PACTG P1042S: CORRELATES OF MEDICATION ADHERENCE IN CHILDREN & ADOLESCENTS W/HI$4,835
M01 · FY2006 · RR · contact PI
ANTIRETROVIRAL THERAPY PHARMACOKINETICS DURING PUBERTY$4,264
M01 · FY2006 · RR · contact PI
ACTG #219C: PEDIATRIC LATE OUTCOMES PROTOCOL$178,010
M01 · FY2005 · RR
PACTG P1025: PERINATAL CORE PROTOCOL$98,241
M01 · FY2005 · RR
PACTG P1015: INTENSIFICATION OF HIV-SPECIFIC CD4 &CD8 ACTIVITY BY CYCLING HAART$50,006
M01 · FY2005 · RR
PACTG P1021: EMTRICITABINE IN COMBINATION WITH EFAVIRENZ &DIDANOSINE$15,854
M01 · FY2005 · RR
PACTG P1045: MORPHOLOGIC &METABOLIC ABNORMALITIES IN VERTICALLY HIV-INFECTED$14,636
M01 · FY2005 · RR
PACTG P1026S: PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUG DURING PREGNANC$12,561
M01 · FY2005 · RR
PACTG 1034: PROTEASE-CONTAINING AND PROTEASE-SPARING HAART REGIMENS$8,536
M01 · FY2005 · RR
PACTG P1042S: CORRELATES OF MEDICATION ADHERENCE IN CHILDREN &ADOLESCENTS W/HI$4,877
M01 · FY2005 · RR
PACTG 1020A: BMS-232632 IN COMB REGIMENS IN ART-NAIVE &EXPERIENCED HIV CHILDRE$915
M01 · FY2005 · RR
ACTG #219C: Pediatric Late Outcomes Protocol$122,256
M01 · FY2004 · RR
PACTG P1025: PERINATAL CORE PROTOCOL$45,760
M01 · FY2004 · RR
Intensification of HIV-Specific CD4 &CD8 Activity$31,259
M01 · FY2004 · RR
Emtricitabine in Combination with Efavirenz &Didanosine$12,157
M01 · FY2004 · RR
BMS-232632 in Comb. Regimens in ART-HIV Children$6,512
M01 · FY2004 · RR
ATCT #326: Alvac HIV Vaccine in Children Born to HIV-Infected Mothers$1,737
M01 · FY2004 · RR
MECHANISMS LEADING TO DECLINE OF HIV SPECIFIC CTL$333,281
R01 · FY2000 · AI